The global gene delivery technologies market size is estimated at USD 5.35 billion in 2024, grew to USD 6.19 billion in 2025 and is predicted to surpass around USD 22.79 billion by 2034, expanding at a CAGR of 15.59% between 2024 and 2034. The North America gene delivery technologies market size accounted for USD 2.25 billion in 2024 and is anticipated to grow at a fastest CAGR of 15.74% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Gene Delivery Technologies Market
5.1. COVID-19 Landscape: Gene Delivery Technologies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Gene Delivery Technologies Market, By Delivery System
8.1. Gene Delivery Technologies Market, by Delivery System, 2024-2034
8.1.1 Viral Gene Delivery Systems
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Non-Viral Gene Delivery System
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Combined Hybrid Delivery Systems
8.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Gene Delivery Technologies Market, By Application
9.1. Gene Delivery Technologies Market, by Application, 2024-2034
9.1.1. Gene therapy
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Cell therapy
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Vaccines
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Research
9.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Gene Delivery Technologies Market, By Method
10.1. Gene Delivery Technologies Market, by March, 2024-2034
10.1.1. Ex Vivo
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. In Vivo
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. In Vitro
10.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Gene Delivery Technologies Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.1.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Forecast, by Method(2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Method(2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Method(2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.2.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Forecast, by Method(2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Method(2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Method(2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Method(2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Method(2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.3.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Forecast, by Method(2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Method(2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Method(2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Method(2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Method(2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Forecast, by Method(2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Method(2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Method(2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Method(2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Method(2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Forecast, by Method(2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Method(2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Delivery System (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Method(2021-2034)
Chapter 12. Company Profiles
12.1. Pfizer, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Becton, Dickinson and Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Thermo Fisher Scientific, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. QIAGEN
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Horizon Discovery Group Co.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. OriGene Technologies, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. SignaGen Laboratories
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Bio-Rad Laboratories, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample